Key result
Blood and imaging biomarkers show promise for early diagnosis of acute myocarditis and inflammatory cardiomyopathy.
Why the study?
Early and accurate diagnosis remains challenging due to high heterogeneity, and existing diagnostic methods are at times expensive, invasive, and not performed early enough, highlighting the need for accurate, cost-effective biomarkers.
This review highlights the potential of various blood and imaging biomarkers to improve the early diagnosis and prognostic assessment of patients with acute myocarditis and chronic inflammatory cardiomyopathy.
May support noninvasive myocarditis evaluation; leaves open prospective validation before clinical adoption.
Myocarditis is a disease caused by cardiac inflammation that can progress to dilated cardiomyopathy, heart failure, and eventually death. Several etiologies, including autoimmune, drug-induced, and infectious, lead to inflammation, which causes damage to the myocardium, followed by remodeling and fibrosis. Although there has been an increasing understanding of pathophysiology, early and accurate diagnosis, and effective treatment remain challenging due to the high heterogeneity. As a result, many patients have poor prognosis, with those surviving at risk of long-term sequelae. Current diagnostic methods, including imaging and endomyocardial biopsy, are, at times, expensive, invasive, and not always performed early enough to affect disease progression. Therefore, the identification of accurate, cost-effective, and prognostically informative biomarkers is critical for screening and treatment. The review then focuses on the biomarkers currently associated with these conditions, which have been extensively studied via blood tests and imaging techniques. The information within this review was retrieved through extensive literature research conducted on major publicly accessible databases and has been collated and revised by an international panel of experts. The biomarkers discussed in the article have shown great promise in clinical research studies and provide clinicians with essential tools for early diagnosis and improved outcomes.
No takes yet. Share an insight, caveat, or question.
Crisci et al. (2023) conducted a review in Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. Biomarkers (blood tests and imaging techniques) was evaluated. Biomarkers evaluated via blood tests and imaging techniques show great promise for early diagnosis and improved outcomes in acute myocarditis and chronic inflammatory cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: